Phase 2 N=30 Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved ASAS20 Response — 59.2; 24.5 Percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Phase 2 N=54 Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
Leukemia
Primary: Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate — 42; 1; 17; 1 participants
Phase 2 N=32 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
Myelodysplastic Syndrome · Chronic Myelomonocytic Leukemia
Primary: Participants With a Complete Remission (CR) — 8; 3; 0; 0 Participants
Phase 2 N=25 Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
Cancer · Brain Metastases
Primary: Percentage of Participants With Distant Brain Failure (DBF) at One Year — 37 percentage of participants
Phase 2 N=45 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
Anal Cancer
Primary: Locoregional Failure Rate at 3 Years — 42; 20 percentage of participants
Phase 2 N=43 Treatment of Cocaine Dependence With Lisdexamfetamine
Cocaine Dependence
Primary: Cocaine-positive Urine Results — 86.5; 92.4 percentage of BE urine tests
Phase 2 N=436 Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee
Knee Osteoarthritis
Primary: Change in WOMAC A — -91.8; -110.0; -109.8; -93.7 units on a scale — p=<0.05
Phase 2 N=210 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Previously Treated Myelodysplastic Syndrome · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Participants With Grades II-IV Acute GVHD — 44; 34; 32 Participants — p=0.09
Phase 2 N=110 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment. — 2 percentage of participants
Phase 2 N=95 A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
Breast Cancer
Primary: Cohorts 1 and 2: Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation…
Phase 2 N=42 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)
Hepatitis C Infection
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) — 12.5; 66.7; 62.5; 62.5 percentage of participants
Phase 2 N=30 Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
Graft vs. Host Disease
Primary: T Regulatory Cell (Treg)/Total Cluster of Differentiation 4 (CD4)+ Ratio — 13; 11 ratio
Phase 2 N=18 A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
Chronic Hepatitis C
Primary: Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died — 0; 0; 0; 0 participants
Phase 2 N=38 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Objective Response Rate — 3 percentage of patients with response